Sajid, et al., published in the journal Science Translational Medicine about the development of a promising mRNA vaccine, 19ISP, which has been found to induce tick resistance and prevent transmission of the Lyme disease-causing agent, Borrelia burgdorferi (Bb).
Search Results for: vaccines
NC Department of Health and Human Services has offered information advising how patients can locate services for monoclonal antibodies treatment for COVID-19 infections. The NCDHHS website states, “The Food and […]
Findings of a recent study, Comparison of two highly-effective mRNA vaccines for COVID-19 during periods of Alpha and Delta variant prevalence, show that Moderna’s COVID-19 vaccine appears to have a […]
From LDA President Pat Smith’s Blog: When the CDC announced a webinar offering continuing education for health care providers for Lyme Awareness Month, some thought it would provide much needed education for doctors about the reality of Lyme disease for patients and what the CDC could do to actually help. Many thought CDC would seek patient input for this program. So what really happened on the webinar?
The development of a national strategy on vector-borne diseases including tick-borne diseases was mandated by Congress. To inform development of the national strategy to address vector-borne diseases, HHS is issuing this Request for Information (RFI).
The Lyme Disease Association Inc. is working with US Biologic to promote Lyme Disease Awareness with Biologic’s new awareness brochure and new flyer. Anyone can download and print both for free. Working together we can help to stop this disease that is affecting 476,000 people annually in the U.S. Click on the Read More below to go to the links to download the information.
Pfizer has received priority review for their vaccine, TicoVac, that protects against tick-borne encephalitis. This tick-borne virus can cause meningitis and trigger long-term neurological symptoms. If approved, the vaccine would potentially protect travelers as well as members of the US military that are deployed to regions where the virus is common, such as Europe and parts of Asia.
Valneva and Pfizer announced that they have initiated a Phase 2 study for their Lyme disease vaccine candidate. This new study builds on previous studies, including new dose regimens as well as being the first clinical study to include children between the ages 5-17 years.
A peer-reviewed report co-authored by Melissa C Fesler and Raphael B Stricker has been published in the International Journal of General Medicine which evaluates pre-exposure prophylaxis (PrEP) using medications approved for use in pregnant women to prevent gestational problems and severe illness in this high-risk population.
Update 2/27/21: The FDA has approved J&J’s Covid-19 vaccine for emergency use Feb. 24, 2021 – the Food & Drug Administration (FDA) has indicated Johnson & Johnson’s COVID-19 vaccine has […]